EPCAM: A Strategy to Enable Manufacturing-Process Control Transformation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EPCAM: A Strategy to Enable Manufacturing-Process Control Transformation
Enterprise process control and management (EPCAM) is a new strategy for healthcare manufacturers based on recent process-control breakthroughs in the electronics industry.


Pharmaceutical Technology


Many developments in the industry indicate that this is the proper course:

  • Products are becoming more complex. Supply chains that remain at a low process sigma and low process capability would result in high yield losses, unreliable supply, and increased likelihood that out-of-specification product reaches the patient. Product complexity comes in the form of biologic drugs, drug–device combinations, and time-released products.
  • FDA is encouraging improved process control and acknowledging that some of its regulations have been obstacles to this goal. The agency is encouraging manufacturers to adopt PAT and decreasing approval times for new products filed with this type of process control.
  • Mapping the human genome means that the ability to determine drug efficacy based upon genetic makeup will decrease the number of blockbuster drugs. Industry supply chains will need to make more products at lower volumes. Process capabilities must improve for companies to efficiently produce this mix of products.
  • Because products' complexity is increasing and their side effects are growing more acute, the industry and FDA are becoming increasingly concerned about spikes in dosing. These concerns are inspiring the development of active delivery mechanisms that increase the demands on the supply chain's process capability.

Improving process capability significantly can be a daunting task, but current technologies make this project more feasible and faster to complete. In the past, regulators' conservative approach discouraged innovation, but today they are willing to assist and encourage transformation. This support is based on the belief that increased scientific understanding and applied technologies reduce variation and risk.

EPCAM integrates information

EPCAM integrates information through a combination of open applications, integration software, and adaptive process-control software. Integrated information enables the macro management process to improve manufacturing processes. The following results occur when EPCAM is fully implemented in both manufacturing and product-development environments:
  • CpK improves from the typical level of 0.7–1 to > 2
  • Process sigma improves from roughly 2 to about 4.5
  • Costs of compliance and nonconformances decrease sharply, and the possibility of recalls is greatly minimized
  • The reliability and speed of new product launches are greatly improved
  • Manufacturing throughput is increased.


Table I: Process-control hierarchy.
Many EPCAM software components support open standards and are not proprietary. EPCAM works with most installations of commercially available software (MES, ERP, and LIMS). Two proprietary applications, APC and FDC, will be discussed in more detail. Companies want to achieve the level of quality that EPCAM process control failitates, but they are uncertain about how to make the transition from the current environment to the targeted EPCAM end state. To make this change, the authors have developed a phased approach that progresses through five logical levels of control (see Table I).


Table II: Transformation demands from the current state to the desired state using EPCAM.
The achievement of each level improves quality and control and leads to business benefits such as greater yields and better products. In addition, organizational capability (e.g., process skills, experimentation skills, the number of experienced people) grows with the attainment of each level. When companies reach levels 4 and 5, their organizational capability and process-control skills must keep pace with their technological advancement. It is absolutely critical to build the organization's process-control expertise, discipline, and the culture of control in both the manufacturing, product-development, and information-technology organizations as progress is made.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here